5-HT₃ receptor antagonists

Bibliography

• GADDUM JH, PICARELLI ZP: Two kinds of tryptamine receptor. Br. J. Pharmacol. (1957) 12:323–328.
   PubMed Web of Science ®Google Scholar
• DERKACH V, SURPRENANT A, NORTH RA: 5-11T3 receptors are membrane ion channels. Nature (1989) 339:706–709.
   PubMed Web of Science ®Google Scholar
• PETERS JA, MALONE HM, LAMBERT JJ: Recent advances in the electrophysiological characterization of 5-11T3 receptors. Trends Pharmacol. ScL (1992) 13:391–397.
   PubMed Web of Science ®Google Scholar
• FOZARD JR: MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors. Naunyn Schmiedebergs Arch. Pharmacol. (1984) 326:36–44.
   PubMed Web of Science ®Google Scholar
• RICHARDSON BP, ENGEL G, DONATSCH P, STADLER PA: Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature (1985) 316: 126–131.
   PubMed Web of Science ®Google Scholar
• BUTLER A, HILL JM, IRELAND SJ, JORDAN CC, TYERS MB: Pharmacological properties of GR38032F, a novel antagonist at 5-11T3 receptors. Br. J. Pharmacol. (1988) 94:397–412.
   PubMed Web of Science ®Google Scholar
• SANGER GJ, NELSON DR: Selective and functional5-hydroxytryptamine3 receptor antagonism by BRL 43694 (granisetron). Eur. J. Pharmacol. (1989) 159:113–124.
   PubMed Web of Science ®Google Scholar
• MINER WD, SANGER GJ: Inhibition of cisplatin-inducedvomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br. J. Pharmacol. (1986) 88:497–499.
   PubMed Web of Science ®Google Scholar
• COSTALL B, DOMENEY AM, NAYLOR RJ, TATTERSALL FD: 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology (1986) 25:959–961.
   PubMed Web of Science ®Google Scholar
• MARICQ AV, PETERSON AS, BRAKE AJ, MYERS RM, JULIUS D: Primary structure and functional expression of the 5HT3 receptor, a serotonin-gated ion channel. Science (1991) 254:432–437.
   PubMed Web of Science ®Google Scholar
• •First report of the cloning of the 5-HT3 receptor.
   Google Scholar
• CHANGEUX JP, GALZI JL, DEVILLERS-THIERY A, BERTRAND D: The functional architecture of the acetyl-choline nicotinic receptor explored by affinity labelling and site-directed mutagenesis. Q. Rev. Biophys. (1992) 25:395–432.
   PubMed Web of Science ®Google Scholar
• BOESS FG, BEROUKHIM R, MARTIN IL: Ultrastructure of the 5-hydroxytryptamine3 receptor. J. Neurochem. (1995) 64:1401–1405.
   PubMed Web of Science ®Google Scholar
• BELELLI D, BALCAREK JM, HOPE AG, PETERS JA, LAMBERT JJ, BLACKBURN TP: Cloning and functional expression of a human 5-hydroxytryptamine Type 3A5 receptor subunit. Mol. Pharmacol. (1995) 48:1054–1062.
   PubMed Web of Science ®Google Scholar
• MIYAKE A, MOCHIZUKI S, TAKEMOTO Y, AKUZAWA S:Molecular cloning of human 5-hydroxytryptamine3 receptor: heterogeneity in distribution and function among species. Mol. Pharmacol (1995) 48:407–416.
   PubMed Web of Science ®Google Scholar
• HOPE AG, PETERS JA, BROWN AM, LAMBERT JJ, BLACKBURN TP: Characterization of a human 5-hydroxytryptamine3 receptor type A (h5-HT3R-AS) subunit stably expressed in HEK 293 cells. Br. J. Pharmacol. (1996) 118:1237–1245.
   PubMed Web of Science ®Google Scholar
• BARNES JM, BARNES NM, COSTALL B, IRONSIDE JW, NAYLOR RJ: Identification and characterisation of 5-hydroxytryptamine 3 recognition sites in human brain tissue. J. Neurochem. (1989) 53:1787–1793.
   PubMed Web of Science ®Google Scholar
• ABI-DARGHAM A, LARUELLE M, WONG DT, ROBERTSONDW, WEINBERGER DR, KLEINMAN JE: Pharmacological and regional characterization of [311]LY278584 binding sites in human brain. J. Neurochem. (1993) 60:730–737.
   PubMed Web of Science ®Google Scholar
• BUFTON KE, STEWARD LJ, BARBER PC, BARNES NM: Distribution and characterization of the PHIgranisetron-labelled 5-11T3 receptor in the human forebrain. Neuropharmacology (1993) 32:1325–1331.
   PubMed Web of Science ®Google Scholar
• FLETCHER S, BARNES NM: Desperately seekingsubunits: are native 5-11T3 receptors really homomeric complexes? Trends Pharmacol. Sci. (1998) 19:212–215.
   Google Scholar
• DAVIES PA, PISTIS M, HANNA MC et al: The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature (1999) 397:359–363.
   PubMed Web of Science ®Google Scholar
• •Cloning of the second subunit of the 5-HT3 receptor.
   Google Scholar
• KILPATRICK GJ, BUNCE KT, TYERS MB: 5-11T3 receptors. Med. Res. Rev. (1990) 10:441–475.
   PubMed Web of Science ®Google Scholar
• MORALES M, BATTENBERG E, DE LECEA L, SANNA PP,BLOOM F: Cellular and subcellular immunolocaliza-tion of the Type 3 serotonin receptor in the rat central nervous system. Brain Res. Mol. Brain Res. (1996) 36:251–260.
   PubMedGoogle Scholar
• MORALES M, BATTENBERG E, BLOOM FE: Distributionof neurons expressing immunoreactivity for the 5HT3 receptor subtype in the rat brain and spinal cord. J. Comp. Neurol. (1998) 402:385–401.
   PubMed Web of Science ®Google Scholar
• TECOTT LH, MARICQ AV, JULIUS D: Nervous system distribution of the serotonin 5-11T3 receptor mRNA. Proc. Natl. Acad. ScL USA (1993) 90:1430–1434.
   PubMed Web of Science ®Google Scholar
• JOHNSON DS, HEINEMANN SF: Embryonic expressionof the 5-11T3 receptor subunit, 5-HT3R-A, in the rat: an in situ hybridization study. Mol. Cell. NeuroscL (1995) 6:122–138.
   PubMed Web of Science ®Google Scholar
• KIA HK, MIQUEL MC, MCKERNAN RM et al.: Localization of 5-11T3 receptors in the rat spinal cord: immunohis-tochemistry and in situ hybridization. Neuroreport (1995) 6:257–261.
   PubMed Web of Science ®Google Scholar
• GREENSHAW AJ: Behavioural pharmacology of 5-11T3 receptor antagonists: a critical update on therapeutic potential. Trends Pharmacol. ScL (1993) 14:265–270.
   PubMed Web of Science ®Google Scholar
• GREENSHAW AJ, SILVERSTONE PH: The non-antiemeticuses of Serotonin 5-11T3 receptor antagonists. Drugs (1997) 53:20–39.
   PubMed Web of Science ®Google Scholar
• JONES BJ, PIPER DC: 5-11T3 receptor antagonists inanxiety. In: 5-HT3 Receptor Antagonists. King FD, Jones BJ, Sanger GJ. (Eds.) CRC Press, Inc., (1994):155–179.
   Google Scholar
• BARNES NM, SHARP T: A review of central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083–1152.
   PubMed Web of Science ®Google Scholar
• •Recent comprehensive review of 5-HT receptors.
   Google Scholar
• ANDREWS PLR, DAVIS CJ, BINGHAM S, DAVIDSON HIM, HAWTHORN J, MASKELL L: The abdominal visceral innervation and the emetic reflex: pathways, pharma-cology and plasticity. Can. J Physiol. Pharmacol (1990) 68:325–345.
   PubMed Web of Science ®Google Scholar
• SORBE B: 5-11T3 receptor antagonists as antiemetic agents in cancer chemotherapy. Exp. Opin. Invest. Drugs (1996) 5:389–407.
   Google Scholar
• LEESER J, LIP H: Prevention of postoperative nausea and vomiting using ondansetron, a new, selective, 5-HT3 receptor antagonist. Anaesth. Analg. (1991) 72:751–755.
   PubMed Web of Science ®Google Scholar
• BODNER M, WHITE PF: Antiemetic efficacy of ondansetron after outpatient laparoscopy. Anesth. Analg. (1991) 73:250–254.
   PubMed Web of Science ®Google Scholar
• LARIJANI GE, GRATZ I, AFHSAR M, MINASSIAN S: Treatment of postoperative nausea and vomiting with ondansetron: a randomized, double-blind comparison with placebo. Anesth. Analg. (1991) 73:246–249.
   PubMed Web of Science ®Google Scholar
• BOUNTRA C, GALE JD, GARDNER CJ et al.: Towards understanding the aetiology and pathophysiology of the emetic reflex: novel approaches to antiemetic drugs. Oncology (1996) 53 (Suppl. 1):102–109.
   Google Scholar
• NAVARI RM, REINHARDT RR, GRALLA RJ et aLReduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl. J. Med. (1999) 340:190–195.
   Google Scholar
• HESKETH PJ, GRALLA RJ, WEBB RT, UENO W, SILBERMAN S: Randomised Phase II study of the neurokinin-1 antagonist, CJ-11,974 for the control of cisplatin-induced emesis. ASCO meeting, Los Angeles, USA (1998). Abstract 199.
   Google Scholar
• FUMOLEAU P, GRAHAM E, GIOVANNINI M, MARTY M,MCQUADE B, VOTAN B: Control of acute cisplatin-induced emesis and nausea with the NK1 receptor antagonist, GR205171, in combinastion with ondansetron. ASCO meeting, Los Angeles USA (1998). Abstract 225.
   Google Scholar
• LADER MH: Ondansetron in the treatment of anxiety. In: Biological Psychiatry. Vol. 2 Proceedings of the 5th World congress of Biological Psychiatry, Florence. Racagni G, Brunello N, Fukuda T (Eds.), Elsevier, Amsterdam, (1990:885–887.
   Google Scholar
• LECRUBIER Y, PUECH AJ, AZCONA A, BAILEY FE, LATASTE X: A randomised double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. Psycho-pharmacology (1993) 112:129–133.
   PubMed Web of Science ®Google Scholar
• MOSCONI M, CHIAMULERA C, RECCHIA G: New anxiolytics in development. Int. J. Clin. Pharm. Res. (1993) 13:331–344.
   PubMedGoogle Scholar
• WHITE A, CORN TH, FEETHAM C, FAULCONBRIDGE C:Ondansetron in treatment of schizophrenia. Lancet (1991) 337:1173.
   PubMed Web of Science ®Google Scholar
• MELTZER HY: Studies of ondansetron in schizo-phrenia. In: Biological Psychiatry. Vol. 2 Proceedings of the 5th World congress of Biological Psychiatry, Florence. Racagni G, Brunello N, Fukuda T (Eds.), Elsevier, Amsterdam, (1990:891–893.
   Google Scholar
• PRESTON GC, MILLSON DC, CUEPPENS PR: Effects of the 5-11T3 receptor antagonist GR68755 on a scopolamine induced cognitive deficit in healthy subjects. Br. J. Clin. Pharmacol. (1991) 32:546.
   Google Scholar
• BUTLER A, ELSWOOD CJ, BURRIDGE J etal: The pharma-cological characterization of 5-11T3 receptors in three isolated preparations derived from guinea-pig tissues. Br. J. Pharmacol (1990) 101:591–598.
   PubMed Web of Science ®Google Scholar
• SANGER GJ, WARDLE KA: Constipation evoked by 5-11T3-receptor antagonism: evidence for heteroge-neous efficacy among different antagonists in guinea-pigs. J. Pharm. Pharmacol (1994) 46:666–670.
   PubMed Web of Science ®Google Scholar
• PEREZ EA: Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.j Gun. Oncol. 13:1036-1034.
   Google Scholar
• MOSS HE, SANGER GJ: The effects of granisetron, ICS205-930 and ondansetron on the visceral pain reflex induced by duodenal distension. Br. J. Pharmacol. (1990) 100:497–501.
   PubMed Web of Science ®Google Scholar
• PRIOR A, READ NW: Reduction of rectal sensitivity andpost-prandial motility by granisetron, a 5 11T3-receptor antagonist, in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (1993) 7:175–180.
   PubMed Web of Science ®Google Scholar
• KILPATRICK GJ, HAGAN RM, OXFORD A, NORTH PC, TYERS MB: GR68755 hydrochloride. Drugs of the future (1992) 17:660–664.
   Google Scholar
• CLAYTON NM, SARGENT R, BUTLER A et al.: The pharma-cological properties of the novel selective 5-11T3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat. Neurogastroenterol. Motil. (1999) 11:207–217.
   PubMed Web of Science ®Google Scholar
• DELVAUX M, LOUVEL D, MAMET JP, CAMPOS-ORIOLA R, FREXINOS J: Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment. Pharmacol. Ther. (1998) 12:849–855.
   PubMed Web of Science ®Google Scholar
• MANGEL AW, NORTHCUTT AR: The safety and efficacy of alosetron, a 5-11T3 receptor antagonist, in female irritable bowel syndrome patients. Aliment. Pharmacol. Ther. (1999) 13 (Suppl. 2):77–82.
   Google Scholar
• GUNPUT MD: Clinical Pharmacology of alosetron. Aliment. Pharmacol. Ther. (1999) 13 (Suppl. 2):70–76.
   Google Scholar
• HUMPHREY PPA, BOUNTRA C, CLAYTON N, KOZLOWSKI K: The therapeutic potential of 5-11T3 receptor antago-nists in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. (1999) 13 (Suppl. 2)31–38.
   Google Scholar
• KRAMER MS, CUTLER N, FEIGHNER J et al.: Distinct mechanism for Antidepressant activity by blockade of central Substance P receptors. Science (1998) 281:1640–1645.
   PubMed Web of Science ®Google Scholar